Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial.
Inderpal S Sarkaria, Linda W Martin, David C Rice...
https://pubmed.ncbi.nlm.nih.gov/37019717/Actively Recruiting
Led by Ann & Robert H Lurie Children's Hospital of Chicago · Updated on 2026-06-05
10
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate the safety and feasibility of using the imaging agent Cytalux pafolacianine combined with near-infrared NIR fluorescence imaging during surgery to remove lung metastases in children aged 6 to 17 years with biopsy-confirmed cancers. Pulmonary metastasectomy is an important treatment for pediatric patients with metastatic solid tumors, and fluorescence-guided surgery may help surgeons identify cancerous nodules more precisely. Cytalux targets folate receptors often expressed by metastatic tumors, potentially improving detection compared to current methods. Participants will receive an intravenous injection of Cytalux at a dose of 0.025 mgkg between 4 and 24 hours before their scheduled lung surgery, which can be either open or minimally invasive. During surgery, standard evaluation techniques will be used first, followed by assessment with NIR fluorescent imaging to identify suspicious nodules. All participants receive Cytalux and undergo NIR imaging to assist in detecting metastatic lesions. Throughout the study, researchers will record the ability of NIR imaging to detect metastatic nodules, including any false positives, within one day of surgery. They will also monitor for any treatment-related adverse events up to 30 days after surgery. Participant involvement includes consenting to the study, receiving the Cytalux injection, undergoing surgery with imaging, and follow-up monitoring to assess safety and effectiveness of the imaging approach.
CONDITIONS
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
T
Timothy Lautz, MD
S
Seth Goldstein, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ann & Robert H Lurie Children's Hospital of Chicago
Lead Sponsor
On Target Laboratories, LLC
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Cytalux Fluorescence Imaging (Investigational) | Current Standard Intraoperative Detection |
|---|---|---|
| What it is | A new method where Cytalux (pafolacianine), a folate analog dye, is injected before surgery, then near-infrared imaging is used to make metastatic nodules in the lungs fluoresce during the operation. This aims to improve nodule identification beyond what is possible with the naked eye. | The current approach involves using CT or PET-CT scans to help plan surgery, followed by the surgeon carefully examining and feeling for nodules during the operation, without fluorescent or molecular imaging agents. |
| Role in the study | Role is to test whether adding Cytalux-enhanced fluorescence can safely help surgeons locate and remove metastatic nodules during planned pulmonary surgery in children with sarcoma and related tumors. | Role is to provide the current established diagnostic method for nodule detection in this population, before the introduction of any investigational imaging agents. |
| Primary clinical use | Used for intraoperative visualization of metastatic lesions in children having surgery for sarcoma or similar tumors with lung metastases, aiming to improve surgical identification and removal of disease. | Used for planning and guiding the surgical removal of pulmonary metastases by relying on preoperative imaging and direct visual/manual detection, which underpins the current standard of pediatric thoracic surgery. |
| How it is given or performed | Cytalux is injected intravenously before surgery at a specified dose for pediatric weight, then during surgery, a near-infrared camera visualizes any nodules that fluoresce, guiding the surgeon for targeted resection. | The surgeon uses recent preoperative chest CT or PET-CT scans for planning, then during surgery, manually inspects and palpates the lungs to find and remove nodules, guided by anatomic landmarks only. |
| Evidence status | Currently being studied for safety, feasibility, sensitivity (true positive rate), and false-positive rate for identifying metastatic lung nodules during surgery in children. No published results for this specific pediatric trial yet, but studies in adults have shown feasibility for intraoperative cancer imaging. | Established as current best practice for pediatric pulmonary metastasectomy. Effectiveness is well accepted for identifying resectable disease, but some small nodules may be missed by the naked eye or tactile search. |
| Important limitations | Safety and benefit in children is not yet established. Some nodules may not take up the fluorescent dye, and false positives may occur. Small trial size and lack of published results mean efficacy and best use are not yet known. | Surgeons may miss very small, deeply embedded, or visually subtle nodules using only manual/visual detection, especially when preoperative imaging is unclear. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive an intravenous injection of Cytalux 4 to 24 hours prior to lung surgery, followed by near-infrared imaging during surgery to help identify metastatic nodules.
1 pre-surgery dosing visit and 1 surgical visit
Duration - 30 days
Participants are monitored for treatment-emergent adverse events for 30 days after surgery.
Approximately 1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Inderpal S Sarkaria, Linda W Martin, David C Rice...
https://pubmed.ncbi.nlm.nih.gov/37019717/Ann & Robert H Lurie Children's Hospital of Chicago
Lead Sponsor
On Target Laboratories, LLC
Collaborating Sponsor